Hostname: page-component-586b7cd67f-g8jcs Total loading time: 0 Render date: 2024-11-24T05:48:40.066Z Has data issue: false hasContentIssue false
  • English
  • Français

A Controlled Study of Lithium vs. Chlorpromazine in Acute Schizophrenics

Published online by Cambridge University Press:  29 January 2018

Baron Shopsin ,
Suk Sik Kim  and
Samuel Gershon
Baron Shopsin
Affiliation:
Neuropsychopharmacology Research Unit, Department of Psychiatry, New York University Medical Center, New York, N.Y. 100016, U.S.A.
Suk Sik Kim
Affiliation:
Manhattan State Hospital, New York
Samuel Gershon
Affiliation:
Neuropsychopharmacology Research Unit, Department of Psychiatry, New York University Medical Center, New York, N.Y. 10016, U.S.A.
Get access Rights & Permissions [Opens in a new window]

Extract

A previous double-blind controlled evaluation of lithium and chlorpromazine in both manic and schizo-affective individuals carried out in this unit (Johnson et al., 1968) indicated that 85 per cent of the schizo-affectives showed a worsening of thought disorder when treated with lithium carbonate, the majority developing symptoms of an acute brain syndrome. The possibility of experimental design accounting for such treatment outcome must be considered.

Type
Research Article
Information
The British Journal of Psychiatry , Volume 119 , Issue 551 , October 1971 , pp. 435 - 440
Copyright
Copyright © The Royal College of Psychiatrists, 1971 

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Angst, J., Dittrich, A., and Grof, P. (1969). ‘Course of affective psychoses and its modification by prophylactic administration of imipramine.’, Int. Pharmacopsychiat., 2, 1–11.Google Scholar
Aronoff, M. S., and Epstein, R. S. (1970). ‘Lithium failure in mania: a clinical study.’ Read at the annual meeting of the American Psychiatric Association, Bal Harbor, Florida, May, 1969. Submitted for publication, 1970.Google Scholar
Baastrup, P. C., and Schou, M. (1967). ‘Lithium as a prophylactic agent: its effect against recurrent depressions and manic-depressive psychosis.’ Arch. gen. Psychiat., 16, 162–7.CrossRefGoogle ScholarPubMed
Burdock, E. I., and Hardesty, A. S. (1968). ‘A psychological test for psychopathology.’ J. abnorm. Psychol., 73, 62–9.CrossRefGoogle ScholarPubMed
Burdock, E. I., and Hardesty, A. S. (1969). ‘A research tactic for evaluation of drug specificity in schizophrenia.’ In Siva Sankar, D. V. (Ed.), Schizophrenia: Current Concepts and Research, New York: P. J. D. Publications.Google Scholar
Fink, M., Klein, D. G., and Kramer, J. C. (1965). ‘Clinical efficacy of chlorpromazine, procyclidine combination, imipramine and placebo in depressive disorders.’ Psychopharmacologia (Berlin), 7, 27–36.Google Scholar
Forssman, H., and Walinder, J. (1969). ‘Lithium treatment on atypical indication.’ Acta psychiat. Scand., Supp. 207, 34–9.Google Scholar
Fries, H. (1969). ‘Experience with lithium carbonate treatment at a psychiatric department in the period 1964–1967.’ Acta psychiat. Scand. Supp. 207, 41–3.Google Scholar
Gattozzi, A. A. (1970). ‘Lithium in the treatment of mood disorders.’ National Clearing House for Mental Health Information, Publication No. 5033.Google Scholar
Gershon, S., and Yuwiler, A. (1960). ‘Lithium ion: A specific pharmacological approach to the treatment of mania.’ J. Neuropsychiat., 1, 229–41.Google Scholar
Glessinger, B. (1954). ‘Evaluation of lithium in treatment of psychotic excitement.’ Med. J. Austral., 41, 277.Google Scholar
Hartigan, G. P. (1963). ‘The use of lithium salts in affective disorders.’ Brit. J. Psychiat., 109, 810–14.Google Scholar
Hekimian, L. J., Gershon, S., Hardesty, A. S., and Burdock, E. I. (1969). ‘Drug efficacy and diagnostic specificity in manic-depressive illness and schizophrenia.’ Dis. new. Syst., 30, 747–51.Google Scholar
Hollister, L. E., Overall, J. E., Johnson, M. J., Shelton, J., Kimbell, I., and Brunse, A. (1966). ‘Amitriptyline alone and combined with perphenazine in newly admitted depressed patients.’ J. nerv. ment. Dis., 142, 460–69.CrossRefGoogle ScholarPubMed
Johnson, G., Gershon, S., and Hekimian, L. J. (1968). ‘Controlled evaluation of lithium and chlorpromazine in the treatment of manic states: an interim report.’ Comp. Psychiat., 9, 563–73.CrossRefGoogle ScholarPubMed
Kline, N. S. (1970). Personal communication.Google Scholar
Lipkin, K. M., Dyrud, J., and Meyer, G. G. (1970). ‘The many faces of mania.’ Arch. gen. Psychiat. 22, 262–8.Google ScholarPubMed
Margulies, M. (1955). ‘Suggestions for the treatment of schizophrenia and manic-depressive patients.’ Med. J. Austral., 1, 137–43.CrossRefGoogle Scholar
Overall, J. E., Hollister, L. E., Meyer, F., Kimbell, I., and Shelton, J. (1964). ‘Imipramine and thioridazine in depressed and schizophrenic patients. Are there specific antidepressant drugs?’ J.A.M.A., 189, 605–8.Google Scholar
Schlagenhauf, G. K., Tupin, J. P., and White, R. B. (1969). ‘Three years experience with lithium carbonate.’ Dis. nerv. Syst. Google Scholar
Serry, M. (1969). ‘Lithium retention and response.’ Lancet, i, 1267–8.Google Scholar
Shopsin, B., Burdock, E., Gershon, S. (1970). ‘Leuco-cytosis during treatment with lithium carbonate.’ Submitted.Google Scholar
Shopsin, B., Gershon, S. (1970). Chemotherapy of manic-depressive illness—Presented at the Symposium of Brain Chemistry and Mental Diseases—Houston, Texas, Nov. 1970.Google Scholar
Shopsin, B., Johnson, G., and Gershon, S. (1970). ‘Neurotoxicity with lithium: Differential drug responsiveness.’ Int. Pharmacopsychiat. Google Scholar
Zall, H., Therman, P. O. G., and Myers, J. M. (1968). ‘Lithium carbonate: A clinical study.’ Amer. J. Psychiat., 125, 549–54.Google Scholar
Submit a response

eLetters

No eLetters have been published for this article.